Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 03 - 10 save search
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes
Published: 2021-03-10 (Crawled : 21:03) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 1.52%
H: 0.19%
C: -1.39%
diabetes treatment fda fda fast track phase 1 therapy trial phase 3 phase 2 fast track fast track designation
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
Published: 2021-03-10 (Crawled : 17:00) - biospace.com/
ABCL | $3.88 -0.77% -0.77% 980K
|
|
| O: 1.27%
H: 5.99%
C: 3.83%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.38%
H: 0.56%
C: -0.69%
covid phase 3 trial
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
Published: 2021-03-10 (Crawled : 13:05) - globenewswire.com
ALGS | $0.735 -7.33% -7.9% 140K
|
Health Technology
|
| O: 0.81%
H: 2.64%
C: -7.13%
hepatitis phase 1 drug phase 3 phase 2 chronic hepatitis b
BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025
Published: 2021-03-10 (Crawled : 12:39) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.98%
H: 0.39%
C: -3.74%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.08%
H: 0.88%
C: -0.65%
phase 1 trial phase 3 phase 2
Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma
Published: 2021-03-10 (Crawled : 12:39) - biospace.com/
ACET | $1.95 -3.7% -3.85% 730K
|
Health Technology
|
| O: 1.56%
H: 2.22%
C: -0.97%
treatment phase 1 trial phase 3 phase 2 t-cell adi-001
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Published: 2021-03-10 (Crawled : 12:39) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.38%
H: 0.56%
C: -0.69%
covid phase 3 trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.